These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29131905)

  • 1. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.
    Hakim A; Gupta R; Ross JS
    JAMA; 2017 Dec; 318(22):2181-2182. PubMed ID: 29131905
    [No Abstract]   [Full Text] [Related]  

  • 2. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs.
    Almeter PJ; Labuhn JA; Morris PE; Hessel EA
    Anesth Analg; 2018 Dec; 127(6):1414-1420. PubMed ID: 29944521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing Pharmaceutical Price Spikes Through Generic Preclearance.
    Sachs RE
    J Leg Med; 2019; 39(2):169-176. PubMed ID: 31503530
    [No Abstract]   [Full Text] [Related]  

  • 6. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 7. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 9. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 12. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R; Wang C
    N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the PPI sample for prescription pharmaceuticals.
    Kelly GG
    Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 16. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 20. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.